GLP-1 receptor agonists now appear in the prescription histories of over 11% of life insurance applicants.
Sometimes it seems there’s no impairment these drugs can’t treat. The FDA continues to approve new GLP-1s and new indications for existing drugs. The pharma industry expects sales of this class to at least double by 2030. That’s good news for them but a challenge for you: Drugs with the same active ingredient can mean anything from cosmetic use to diabetes, chronic kidney disease, or even an increased risk of heart attack.
Join Kyle Schimek and Jenna Fariss in this highly informative webinar to learn how to interpret the presence of GLP-1s—today and over the next few years—so you can accurately assess the mortality implications of drugs you’ll see more and more frequently.
Topics covered
- The unlikely origin story of the drug of the century
- The mechanism of action that curbs hunger and works on everything from MASH to sleep apnea
- What’s new and what’s next for GLP-1s: Recently approved uses and promising research on common conditions from osteoporosis to substance use disorder
- Exploiting digital underwriting evidence to pinpoint which impairment—of many—is implied by the presence of a GLP-1 on any profile
Who should attend
Underwriters, insurance industry medical directors, reinsurers, and anyone interested in keeping abreast of a drug class that has profound mortality implications for a large percentage of the insured population.
When
Tuesday, February 10, 2026, 11 a.m. Central
Kyle Schimek, PharmD, BCPS
Manager, Clinical Services, Milliman IntelliScript
Jenna Fariss, ASA, MAAA
Principal and Actuary, Milliman IntelliScript
